Omnitrope Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Omnitrope is a daily injectable treatment containing human growth hormone (HGH), designed to help individuals with growth hormone deficiencies or conditions that affect growth. It supports bone and muscle development, addressing conditions such as growth hormone deficiency in both children and adults, Turner syndrome, and growth impairments related to chronic kidney disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types in the omnitrope market are injection and oral formulations. Omnitrope injection refers to recombinant human growth hormone (somatropin) administered through subcutaneous injection. It is used for various conditions, including growth hormone deficiency, Turner syndrome, chronic renal insufficiency, small for gestational age, and others. Omnitrope is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The omnitrope market research report is one of a series of new reports from The Business Research Company that provides omnitrope market statistics, including omnitrope industry global market size, regional shares, competitors with an omnitrope market share, detailed omnitrope market segments, market trends, and opportunities, and any further data you may need to thrive in the omnitrope industry. This omnitrope market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The omnitrope market size is expected to see rapidly growth in the next few years. It will grow to $6,300.6 million in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to ongoing advancements in biotechnology, development of new formulations and delivery mechanisms, increasing focus on personalized medicine, expanding indications for growth hormone therapy, ongoing clinical research into new therapeutic uses, strategic collaborations and partnerships. Major trends in the forecast period include governments focusing on enhancing their biopharmaceutical sectors, needle-free delivery systems innovations, rising adoption of biosimilars, smart injectors innovations, targeted therapies, early diagnosis and intervention, personalized treatment approaches.

The rising prevalence of growth hormone deficiency (GHD) is expected to drive market expansion for omnitrope in the coming years. GHD, a condition where the body produces insufficient growth hormone, leads to impaired growth and other related health issues. The increasing incidence of GHD is largely attributed to improved diagnostic methods and heightened awareness among healthcare providers and the general public. Omnitrope, a recombinant human growth hormone, aids in the management of GHD by promoting growth, enhancing muscle mass, and improving bone density. These benefits help normalize physical development and improve the quality of life for those affected by the condition. For example, as reported by the Council of Health Insurance in Saudi Arabia, in 2022, the national prevalence of short stature was 33.68%, with growth hormone deficiency being the primary endocrinological cause in 9.7% of cases. This growing incidence of GHD is a key driver for the expansion of the omnitrope market.

The increasing adoption of biosimilars is anticipated to further fuel the growth of the omnitrope market. Biosimilars are biologic medical products that closely resemble an already approved reference biologic, with no clinically significant differences in safety, purity, or efficacy. The rise in biosimilar adoption is driven by their cost-effectiveness, comparable efficacy to reference biologics, and expanding support from regulatory bodies and healthcare providers focused on reducing healthcare expenditures. Omnitrope, as a recombinant human growth hormone, offers a clinically proven, cost-effective alternative to branded growth hormone therapies, enhancing patient access to necessary treatments. This, in turn, supports the biosimilars sector by demonstrating the viability of safe, effective substitutes for complex biologic drugs. For instance, according to the Association for Accessible Medicines (AAM), in 2023, biosimilar use generated over $12.4 billion in savings, marking a 30% increase from the previous year. This growing adoption of biosimilars is a significant driver for the omnitrope market.

In October 2023, Novartis AG, a Switzerland-based pharmaceutical corporation, completed the spin-off of Sandoz, its Generics and Biosimilars division, for an undisclosed amount. This strategic move allowed Novartis to streamline its focus on innovative pharmaceuticals, while enabling Sandoz to operate as an independent entity in the generics and biosimilars market. The spin-off is designed to enhance the strategic agility, operational efficiency, and shareholder value of both companies. Sandoz, also based in Switzerland, is known for developing Omnitrope.

Key player operating in the omnitrope market is Sandoz International GmbH

North America was the largest region in the omnitrope market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in omnitrope report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the omnitrope market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The omnitrope market consists of sales of biosimilars of omnitrope, cartridges, ReoPro compounding kits, vials, and powder. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Omnitrope Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on omnitrope market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for omnitrope ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The omnitrope market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Injection; Oral
• 2) By Application: Growth Hormone Deficiency; Turner Syndrome; Chronic Renal Insufficiency; Small For Gestational Age; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Sandoz International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.